Morgan Stanley Albireo Pharma, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.01 - $23.78 $385,954 - $509,605	21,430 Added 17.42%	144,423 $3.12 Million
Q3 2022 Nov 14, 2022	SELL	$16.32 - $26.37 $505,675 - $817,074	-30,985 Reduced 20.12%	122,993 $2.38 Million
Q2 2022 Oct 27, 2022	BUY	$18.54 - $37.29 $1.85 Million - $3.72 Million	99,678 Added 183.57%	153,978 $3.06 Million
Q2 2022 Aug 15, 2022	BUY	$18.54 - $37.29 $1.85 Million - $3.72 Million	99,678 Added 183.57%	153,978 $3.06 Million
Q1 2022 Oct 27, 2022	SELL	$23.94 - $33.74 $2.39 Million - $3.36 Million	-99,678 Reduced 64.74%	54,300 $1.62 Million
Q1 2022 May 13, 2022	BUY	$23.94 - $33.74 $337,721 - $475,970	14,107 Added 35.1%	54,300 $1.62 Million
Q4 2021 Feb 14, 2022	BUY	$21.19 - $31.29 $446,007 - $658,591	21,048 Added 109.94%	40,193 $936,000
Q3 2021 Nov 15, 2021	BUY	$27.36 - $35.98 $523,807 - $688,837	19,145 New	19,145 $597,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.